Janssen Search
Search results
ASH 2020 Newsroom
The American Society of Hematology (ASH) has moved to a virtual platform for the 2020 Annual Meeting, and Janssen Oncology will have a strong showing at ASH with more than 35 company-sponsored presentations highlighting our deep, diverse oncology pipeline ...
John C. Reed, M.D., Ph.D.
JOHN C. REED, M.D., PH.D. EXECUTIVE VICE PRESIDENT PHARMACEUTICALS, R&D JOHNSON & JOHNSON As Executive Vice President, Pharmaceuticals, R&D and Johnson & Johnson (J&J) Executive Committee member, John’s mission is to focus the best ...
TREMFYA® (guselkumab) demonstrates superiority versus STELARA® (ustekinumab) in Phase 3 Crohn's disease program
May 23, 2024 Data from GALAXI 2 & 3 showed TREMFYA® was superior to STELARA® in all pooled endoscopic endpoints Washington, D.C. (May 21, 2024) – Johnson & Johnson today announced the first Phase 3 results for TREMFYA® (guselkumab) in adult ...
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Jul 22, 2024 Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of ...
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
Aug 29, 2024 United States Marks first FDA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies Filing based on the Phase 3 Vivacity-MG3 program, the ...
TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
Sep 11, 2024 United States The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program [1], [2], ...
Johnson & Johnson Announces Expansion of IMBRUVICA® (ibrutinib) Label in the U.S. to Include Oral Suspension Formulation for Adult Patients in its Approved Indications
Feb 26, 2024 United States IMBRUVICA ® is now the only Bruton’s tyrosine kinase inhibitor (BTKi) approved with an oral suspension formulation, providing additional flexibility for patients who may have difficulty swallowing tablets or capsules HORSHAM, PA ...
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
Feb 23, 2024 Belgium Results from the Phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment [1] Most patients with multiple ...
Janssen Signs with Yale Open Data Access
Janssen Signs First-of-its-Kind Agreement With Yale School of Medicine’s Open Data Access Project Janssen Research & Development (R&D) signed a first-of-its-kind agreement with Yale School of Medicine’s Open Data Access (YODA) Project to ...
Story – Cork Lower Harbour Energy Group
Cork Lower Harbour Energy Group In 2008 Janssen began collaborating with DePuy Synthes, GlaxoSmithKline (GSK) and Novartis to form the Cork Lower Harbour Energy Group (CLHEG), a unique industry collaboration focused on developing a green solution to ...